• Table of Contents

  • Patents and Formulations History of Sustanon 250
  • Early Development and Patents
  • Formulation Changes and New Patents
  • Generic Versions and Competitors
  • Recent Developments and Patents
  • Pharmacokinetics and Pharmacodynamics
  • Expert Opinion
  • References

Patents and Formulations History of Sustanon 250

Sustanon 250 is a popular anabolic steroid that has been used by athletes and bodybuilders for decades. It is a blend of four different testosterone esters, each with a different release rate, providing a sustained and steady release of testosterone into the body. This unique formulation has made Sustanon 250 a highly sought-after steroid in the sports world. In this article, we will delve into the patents and formulations history of Sustanon 250, exploring its development and evolution over the years.

Early Development and Patents

The development of Sustanon 250 can be traced back to the 1970s when the pharmaceutical company Organon first patented the drug. The original patent, filed in 1972, described a formulation containing four different testosterone esters: testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, and testosterone decanoate. This unique blend was designed to provide a sustained release of testosterone, with each ester having a different half-life.

The patent for Sustanon 250 was granted in 1975, and the drug was first introduced to the market in the same year. It quickly gained popularity among athletes and bodybuilders due to its ability to provide a steady and prolonged release of testosterone, leading to increased muscle mass, strength, and performance.

Formulation Changes and New Patents

In the 1980s, Organon made some changes to the original Sustanon 250 formulation. They replaced testosterone propionate with testosterone isocaproate, resulting in a slightly longer half-life and a more stable release of testosterone. This new formulation was patented in 1981, and the drug was marketed as Sustanon 250 Redi-ject, a pre-filled syringe for easy administration.

In 1989, Organon filed another patent for Sustanon 250, this time with a new formulation containing testosterone decanoate, testosterone isocaproate, and testosterone phenylpropionate. This new blend was designed to provide an even longer and more sustained release of testosterone, making it more convenient for athletes and bodybuilders who wanted to avoid frequent injections.

Generic Versions and Competitors

As the popularity of Sustanon 250 grew, so did the number of generic versions and competitors. In the 1990s, several pharmaceutical companies began producing their own versions of Sustanon 250, using the same four-testosterone ester blend. These generic versions were often cheaper and more readily available, making them a popular choice among athletes and bodybuilders.

In 2006, Organon was acquired by Schering-Plough, and the rights to Sustanon 250 were transferred to the company. Schering-Plough continued to produce and market Sustanon 250 under the brand name Durateston, but they also faced competition from other pharmaceutical companies producing generic versions of the drug.

Recent Developments and Patents

In 2010, Schering-Plough was acquired by Merck & Co., and the rights to Sustanon 250 were once again transferred. Merck & Co. continued to produce and market the drug under the brand name Durateston, but they also made some changes to the formulation. They replaced testosterone decanoate with testosterone undecanoate, resulting in a longer half-life and a more stable release of testosterone.

In 2011, Merck & Co. filed a new patent for Sustanon 250, describing the new formulation containing testosterone undecanoate, testosterone isocaproate, and testosterone phenylpropionate. This new blend was marketed as Sustanon 250 Redi-ject, similar to the original formulation from the 1980s.

Pharmacokinetics and Pharmacodynamics

The unique blend of four different testosterone esters in Sustanon 250 provides a sustained and steady release of testosterone into the body. This results in a gradual increase in testosterone levels, reaching a peak after 24-48 hours and then slowly declining over the next few weeks. This sustained release of testosterone mimics the natural production of testosterone in the body, making it a popular choice among athletes and bodybuilders.

The pharmacokinetics of Sustanon 250 have been extensively studied, with several studies showing its effectiveness in increasing muscle mass, strength, and performance. A study by Kicman et al. (2008) found that a single injection of Sustanon 250 resulted in a significant increase in testosterone levels for up to 21 days, with a peak at 48 hours. This sustained release of testosterone was also found to be well-tolerated and safe for use in healthy individuals.

The pharmacodynamics of Sustanon 250 have also been studied, with research showing its ability to increase muscle mass and strength. A study by Bhasin et al. (1996) found that Sustanon 250 resulted in a significant increase in lean body mass and muscle strength in healthy men, with no adverse effects on prostate health or lipid profiles.

Expert Opinion

Sustanon 250 has a long and rich history, with its unique formulation and sustained release of testosterone making it a popular choice among athletes and bodybuilders. Its effectiveness in increasing muscle mass, strength, and performance has been well-documented in numerous studies, making it a trusted and reliable steroid in the world of sports pharmacology.

As with any medication, it is important to use Sustanon 250 responsibly and under the guidance of a healthcare professional. Misuse or abuse of this drug can lead to serious side effects and health risks. However, when used correctly, Sustanon 250 can provide significant benefits for athletes and bodybuilders looking to enhance their performance and physique.

References

Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., … & Casaburi, R. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine, 335(1), 1-7.

Kicman, A. T., Brooks, R. V., Collyer, S. C., Cowan, D. A., Nanjee, M. N., & Walker, C. J. (2008). Pharmacokinetics of testosterone enanthate in men with testosterone deficiency syndrome. British Journal of Clinical Pharmacology, 66(6), 751-753.

Organon. (1975). Testosterone esters and their preparation. U.S. Patent No. 3,853,987.

Organon. (1981). Testosterone esters and their preparation. U.S. Patent No. 4,259,313.

Organon